地氯雷他定治疗320例慢性荨麻疹的临床研究  

A Clinial Trail of Desloratadine on Treating 320 Cases of Chronic Urticaria

作　　者：刘元林[1] 杨闰平[1] 李晓鹏[1] 鲁祖清[1] 

机构地区：[1]海军总医院皮肤科,北京100037

出　　处：《海军总医院学报》2005年第3期149-151,共3页Journal of Naval General Hospital of PLA

摘　　要：目的评价地氯雷他定治疗慢性荨麻疹的疗效及安全性,积累用药经验。方法门诊开放性研究,疗程2周,4级评分评价疗效,记录不良反应。结果共观察320例,总有效率为90%,治疗2周疗效明显优于1周(P<0.001)。不良反应最多为嗜睡(5.5%),全部在2 d内出现。未见任何心脏不良反应。结论地氯雷他定是一种安全、有效的治疗慢性荨麻疹的新型抗组胺药物。Objective To evaluate the therapeutic effects and safety of desloratadine on treating chronic urticaria. Methods During the two-week clinical open trial, the therapeutic effects were evaluated on 4 grade scores, and any side-effect was carefully recorded. Results The total effective rate was 90%. The results at the end of 2 weeks course was significantly better than that at the end of 1 week （P〈0. 001）. The most common side-effect was sleepiness （5.5%）, which appeared within 2 days. No any heart related side-effect was recorded. Conclusion Desloratadine is an efficient and safe antihistaminic drug on treating chronic urticaria.

关 键 词：地氯雷他定 荨麻疹 抗组胺药物 

分 类 号：R976[医药卫生—药品]